Stevens Johnson Syndrome Risks

Stevens Johnson Syndrome RisksStevens Johnson Syndrome RisksStevens Johnson Syndrome Risks
  • Home
  • SJS
  • FDA Drug Reactions
  • Stevens Johnson Syndrome
  • Medication Reaction
  • SJS -Insights
  • More
    • Home
    • SJS
    • FDA Drug Reactions
    • Stevens Johnson Syndrome
    • Medication Reaction
    • SJS -Insights

Stevens Johnson Syndrome Risks

Stevens Johnson Syndrome RisksStevens Johnson Syndrome RisksStevens Johnson Syndrome Risks
  • Home
  • SJS
  • FDA Drug Reactions
  • Stevens Johnson Syndrome
  • Medication Reaction
  • SJS -Insights

Sharing SJS Stevens Johnson Syndrome Information

Sharing SJS Stevens Johnson Syndrome Information Sharing SJS Stevens Johnson Syndrome Information Sharing SJS Stevens Johnson Syndrome Information

 Pharma should conduct through clinical trials and post-market surveillance to identify potential adverse effects from meds



Stevens Johnson Syndrome

Advancing the Understanding of Stevens Johnson Syndrome

At Stevens Johnson Syndrome, we are dedicated to sharing research to identify the underlying causes of this rare and life-threatening skin condition. With a focus on medication-induced cases risk.


 

Symptoms

One to three days before a rash develops, you may show early signs of Stevens-Johnson syndrome, including:

  • Fever
  • A sore mouth and throat
  • Fatigue
  • Burning eyes


As the condition develops, other signs and symptoms include:

  • Unexplained widespread skin pain
  • A red or purple rash that spreads
  • Blisters on your skin and the mucous membranes of the mouth, nose, eyes and genitals
  • Shedding of skin within days after blisters form


 Medications are causative in over 80 percent of cases. Stevens-Johnson syndrome and toxic epidermal necrolysis are distinguished based on the extent of the detached skin surface area.  

Reaction Caused by Drug, Medicine, or Medication

What Drugs can cause Stevens Johnson Syndrome?

 

Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis: Macules, Papules, and Bullae

H Vossos, PM Delgado - Journal of the American Psychiatric …, 2024 - journals.sagepub.com… The objective of this discussion paper is to illuminate the importance of early identification
and treatment of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). SJS/…Save Cite Cited by 1 Related articles All 3 versions 



 Causes: SJS and TEN are typically drug-induced, with common triggers including antibiotics, anticonvulsants, and over-the-counter medications.


You should collect all relevant medical records, prescriptions, and any documentation related to your diagnosis and treatment 



Patient Safety OVER Profit


 This includes not investing in research to understand and mitigate risks of taking a medicine, medication or drug known to cause Stevens Johnson Syndrome. 


About Stevens Johnson Syndrome

Stevens Johnson Syndrome

Stevens Johnson Syndrome described by the National Library of Medicine as “a rare, acute, serious, and potentially fatal skin reaction” in which the skin detaches from the body in painful blisters and rashes on the inside and surface of the body. 

SJS Skin Reaction to Medicine, Medication, or Drug

FDA Reporting Adverse Reaction Events

 Reporting adverse events is essential for effective evaluation and management of health safety data.


It allows regulatory authorities to evaluate safety information and understand the causes of adverse events, leading to improved patient safety.


But first You need to be told that a drug, medicine, or medication caus

FDA-regulated products

Stevens Johnson Syndrome

Stevens Johnson Syndrome Research

  

Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in united states adults. J Invest Dermatol. (2016) 136:1387–97. doi: 10.1016/j.jid.2016.03.023

Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives

on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy

Immunol

  

Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in united states adults. J Invest Dermatol. (2016) 136:1387–97. doi: 10.1016/j.jid.2016.03.023

Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives

on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy

Immunol. (2018) 54:147–76. doi: 10.1007/s12016-017-8654-z



White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton

B, et al. SJS/TEN 2017: Building multidisciplinary networks to drive science and

translation. J Allergy Clin Immunol Pract. (2018) 6:38–69. doi: 10.1016/j.jaip.2017.

11.028



Chang WC, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky

TM, et al. SJS/TEN 2019: From science to translation. J Dermatol Sci. (2020)

98:2–12.



Hasegawa A, Abe R. Recent advances in managing and understanding

Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. (2020)

9:F1000FacultyRev–612. doi: 10.12688/f1000research.24748.1

Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication

use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl

J Med. (1995) 333:1600–7. doi: 10.1056/NEJM199512143332404



Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes

Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis:

Assessment of medication risks with emphasis on recently marketed drugs. The

EuroSCAR-study. J Invest Dermatol. (2008) 128:35–44. doi: 10.1038/sj.jid.57

01033



Blumenthal KG,Wickner PG, Lau JJ, Zhou L. Stevens-Johnson syndrome and

toxic epidermal necrolysis: A cross-sectional analysis of patients in an integrated

allergy repository of a large health care system. J A

llergy Clin Immunol Pract. (2015)

3:277–280.e1. doi: 10.1016/j.jaip.2014.10.002



Davis RL, Gallagher MA, Asgari MM, Eide MJ, Margolis DJ, Macy E, et al.

Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in

electronic health record databases. Pharmacoepidemiol Drug Saf. (2015) 24:684–92.

doi: 10.1002/pds.3778



Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal

A, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: A multicenter

retrospective study of 377 adult patients from the united states. J Invest Dermatol.

(2018) 138:2315–21. doi: 10.1016/j.jid.2018.04.027



de Bustros P, Baldea A, Sanford A, Joyce C, Adams W, Bouchard C. Review of

culprit drugs associated with patients admitted to the burn unit with the diagnosis

of Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Burns.

(2021) S0305-4179(21)00220-5. doi: 10.1016/j.burns.2021.08.009 [Epub ahead of

print].



Ou-Yang C, Agustianty S, Wang HC. Developing a data mining approach

to investigate association between physician prescription and patient outcome –

a study on re-hospitalization in Stevens-Johnson syndrome. Comput Methods

Programs Biomed. (2013) 112:84–91. doi: 10.1016/j.cmpb.2013.07.004

14. Ma DH, Tsai TY, Pan LY, Chen SY, Hsiao CH, Yeh LK, et al. Clinical

aspects of Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular

complications in Taiwan. Front Med (Lausanne). (2021) 8:661891. doi: 10.3389/

fmed.2021.661891



Park CS, Kang DY, Kang MG, Kim S, Ye YM, Kim SH, et al. Severe cutaneous

adverse reactions to antiepileptic drugs: A nationwide registry-based study in

Korea. Allergy Asthma Immunol Res. (2019) 11:709–22. doi: 10.4168/aair.2019.11.

5.7



Fukasawa T, Takahashi H, Kameyama N, Fukuda R, Furuhata S, Tanemura

N, et al. Development of an electronic medical record-based algorithm to

identify patients with Stevens-Johnson syndrome and toxic epidermal necrolysis

in Japan. PLoS One. (2019) 14:e0221130. doi: 10.1371/journal.pone.022

1130



Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson

syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of

the US Food and drug administration adverse event reporting system. Epilepsia.

(2018) 59:2318–24. doi: 10.1111/epi.14591

Stevens Johnson Syndrome a Reaction to Meds

Cause of Skin Reaction

Attach Files
Attachments (0)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stevens Johnson Syndrome

sjsresearchconsortium@gmail.com

Subscribe

Copyright © 2024 Stevens Johnson Syndrome - All Rights Reserved.

  • SJS
  • FDA Drug Reactions
  • Stevens Johnson Syndrome

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept